Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
about
Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)Ontology-supported research on vaccine efficacy, safety and integrative biological networksMonitoring the safety of annual and pandemic influenza vaccines: lessons from the US experience.Importance of background rates of disease in assessment of vaccine safety during mass immunisation with pandemic H1N1 influenza vaccinesAdverse events following pandemic A (H1N1) 2009 monovalent vaccines in pregnant women--Taiwan, November 2009-August 2010.Assessing vaccine safety communication with healthcare providers in a large urban county.Data mining for prospective early detection of safety signals in the Vaccine Adverse Event Reporting System (VAERS): a case study of febrile seizures after a 2010-2011 seasonal influenza virus vaccine.A retrospective population-based study on seizures related to childhood vaccination.Deaths following vaccination: What does the evidence show?Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United StatesAn evaluation of the feasibility and usability of a proof of concept mobile app for adverse event reporting post influenza vaccinationOAE: The Ontology of Adverse Events.Consumer reporting of adverse events following immunization (AEFI): identifying predictors of reporting an AEFI.The Ontology of Vaccine Adverse Events (OVAE) and its usage in representing and analyzing adverse events associated with US-licensed human vaccinesGuillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States.Motor palsies of cranial nerves (excluding VII) after vaccination: reports to the US Vaccine Adverse Event Reporting System.A dose-response relationship between organic mercury exposure from thimerosal-containing vaccines and neurodevelopmental disordersThimerosal-containing hepatitis B vaccination and the risk for diagnosed specific delays in development in the United States: a case-control study in the vaccine safety datalinkOntology-based combinatorial comparative analysis of adverse events associated with killed and live influenza vaccines.The National Vaccine Advisory Committee: reducing patient and provider barriers to maternal immunizations: approved by the National Vaccine Advisory Committee on June 11, 2014Safety of varicella vaccine after licensure in the United States: experience from reports to the vaccine adverse event reporting system, 1995-2005.A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination.Adverse Events Following Measles, Mumps, and Rubella Vaccine in Adults Reported to the Vaccine Adverse Event Reporting System (VAERS), 2003-2013Adolescent Premature Ovarian Insufficiency Following Human Papillomavirus Vaccination: A Case Series Seen in General PracticeThe role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study.The complementary roles of Phase 3 trials and post-licensure surveillance in the evaluation of new vaccines.Vaccine Safety Resources for NursesPhysicians' confidence in vaccine safety studiesUsing Probabilistic Record Linkage of Structured and Unstructured Data to Identify Duplicate Cases in Spontaneous Adverse Event Reporting Systems.Relative trends in hospitalizations and mortality among infants by the number of vaccine doses and age, based on the Vaccine Adverse Event Reporting System (VAERS), 1990-2010Thimerosal-Preserved Hepatitis B Vaccine and Hyperkinetic Syndrome of ChildhoodThe contribution of the vaccine adverse event text mining system to the classification of possible Guillain-Barré syndrome reports.Developmental regression and autism reported to the Vaccine Adverse Event Reporting System.Ontology-based Vaccine and Drug Adverse Event Representation and Theory-guided Systematic Causal Network Analysis toward Integrative Pharmacovigilance ResearchStatistical and Ontological Analysis of Adverse Events Associated with Monovalent and Combination Vaccines against Hepatitis A and B Diseases.The Centers for Disease Control and Prevention's public health response to monitoring Tdap safety in pregnant women in the United StatesHLA type and immune response to Borrelia burgdorferi outer surface protein a in people in whom arthritis developed after Lyme disease vaccination.A two-phase study evaluating the relationship between Thimerosal-containing vaccine administration and the risk for an autism spectrum disorder diagnosis in the United States.Guillain-Barre syndrome during the 2009-2010 H1N1 influenza vaccination campaign: population-based surveillance among 45 million AmericansGlobal safety of vaccines: strengthening systems for monitoring, management and the role of GACVS.
P2860
Q26799634-EA569C7B-A2FD-44CD-84FC-59526F606642Q27005991-2EB96DD9-516C-460B-A792-3162F9482AFDQ30367585-D55D3125-5ABA-41BA-80B5-5B8B4512D9A8Q30382146-16464C14-FAA6-48BD-8855-6933110BAA26Q30406112-E89AF6D3-33D6-43C1-9C0F-17282518A106Q30407586-522A8132-186B-4B11-8E6A-7C154D52110BQ30622918-6D2062D9-B35E-4800-ABE3-8BDBFC45CDC9Q33160174-25F9367D-7239-4074-8430-AC95918AE85CQ33165769-51C348C7-8A24-4933-85A2-9CFC45B81884Q33166996-9766FBDC-F2DF-4C8D-B9AB-47F25D899EB5Q33447372-62112BA7-F5C0-4F80-9014-2B0CB0A9C744Q33997761-C0B60778-976B-4263-904A-869844E20959Q34033938-EA2F0D4F-2B63-4D90-9CB2-55325BC5453BQ34253966-5F40D2A3-83DE-43BB-86EF-7557228E3BA8Q34271547-FE74EA6C-56B9-469F-A783-20B795C4CD51Q34290826-AE1CCE17-1678-4ABF-80FE-24127AFB0768Q34348131-09241D16-4CEA-4A9B-A026-6A3396B38012Q34432373-B8A7B670-01E2-45FF-89C0-2FBCC8E3A081Q34499848-A09E8241-B7A0-44E0-BB2B-8E43AB4BD91BQ34576732-F9960C91-B586-4D48-A1F7-B28049F49AAFQ34590637-B9EACD07-7235-467B-9189-847CA8EDB68FQ35202813-E018CCC2-F1BF-4D10-A445-F3746AEFA08DQ35661817-32178D3A-6844-4B66-A6BB-47CB363D2FCCQ35927665-3D1B2D75-DD7F-4B44-A1E6-3BF1819D924FQ35972250-F7455EB3-31AA-4F6A-9904-543232F671C8Q36131193-87EE0F85-4D7B-40D1-96FF-2F35AE25AE9EQ36142449-F87FD27E-AD04-470F-AEB2-2A9BEF04F9D8Q36175636-F23634D2-0806-48A0-BC64-09D5CEAC7155Q36308128-17FE4E2A-B1F4-4D76-AB29-C36C2A1A16AFQ36540764-4C99D264-3B97-4CA2-A92F-639E9FBF2FF5Q36735514-9D98D853-E7C2-471B-8051-1F3D506E9BE9Q36817854-CB0CA39F-F479-490E-8903-9143FFDDF027Q36893272-CC86A9D2-9C84-49D4-952F-ACE45E3ADAC0Q37118671-812C59C7-48AE-469D-AABE-A368036EC6C7Q37303528-3EDDA3C7-A6F3-454F-ACCF-514AE5055D97Q37320137-6DCF5700-56A4-47EA-B354-B3B5B5D26440Q37361401-DF4D3C1C-9F37-4BA9-81E0-15DC98299FA6Q37425919-84491E9E-D917-49E6-9CD5-26C372CA21AEQ37463235-B2013662-B6AA-4364-ACB9-DFE947FD38CCQ37503234-DCF49789-BDA1-42E3-B84E-E5ECC0FF495D
P2860
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
@ast
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
@en
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
@nl
type
label
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
@ast
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
@en
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
@nl
prefLabel
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
@ast
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
@en
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
@nl
P2093
P1476
Understanding vaccine safety information from the Vaccine Adverse Event Reporting System.
@en
P2093
Frank Destefano
Frederick Varricchio
John Iskander
M Miles Braun
Robert Ball
Robert Pless
Robert T Chen
P304
P356
10.1097/00006454-200404000-00002
P577
2004-04-01T00:00:00Z